August 21, 2026 Type 1 diabetes briefing: trials, device safety, and research signals
A daily Type1Cure briefing built from current official and public source pulls, with each item labeled by source, evidence class, and family relevance.
The short version
The August 21, 2026 feed is strongest in three lanes: device safety, recruiting studies, and recent research records. Type1Cure treats safety and trial records as higher-priority signals because they can affect what a family may need to check, ask, or watch next.
This is not a medical recommendation. It is a source map and plain-English triage layer designed to help families decide what deserves a closer look with their care team.
Signals in the feed
- Medtronic MiniMed, Inc.: MiniMed 640G Insulin Pump, Model: MMT-1711, MMT-1712; — Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypo...Source
- Medtronic MiniMed, Inc.: MiniMed 670G Insulin Pump, Model: MMT-1781, MMT-1782; — Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypo...Source
- Medtronic MiniMed, Inc.: MiniMed 780G Insulin Pump, Model: MMT-1885CLW, MMT-1886CLW — Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypo...Source
- GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes — RECRUITING, NA. Interventions: MiniMed™ NMX8-AID System with DS5™/Simplera Sync™. Locations: Little Rock, Arkansas, United States | Escondido, California, United States | Goleta, California, United States. The purpose o...Source
- Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment — RECRUITING, PHASE2. Interventions: Semaglutide Pen Injector, Placebo. Locations: New Haven, Connecticut, United States. More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of t...Source
- Medtronic MiniMed, Inc.: MiniMed Go App, Model: MMT-8600 (iOS), MMT-8601 (Android) — For MiniMed Go app version 1.0.0 and 1.1.0, when the Set day and night is turned OFF and missed dose or Correct high glucose alerts are enabled, the associated alerts will not be triggered during the nighttime. This cou...Source
- Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes — RECRUITING, PHASE2, PHASE3. Interventions: Dimethyl Fumarate Enteric-coated Capsules, Insulin. Locations: Nanjing, Jiangsu, China. This is a non-randomized, parallel-controlled, single-center, open-label clinical trial...Source
How to use this briefing
Start with the evidence label. Official registry and regulator records are not the same thing as advice, but they are stronger source material than a repost, rumor, or promotional headline.
For trials, check eligibility, location, burden, intervention, and contact details at the original registry. For device safety, check exact product names, models, lot numbers, software versions, and manufacturer instructions.
This article is an evidence-labeled information brief, not medical advice. Use the linked source records and your care team before making treatment decisions.